Skip to content

Medical emergency? What to do

EU clears Roche drugs after probe into lax safety reports

3-RXPublished November 19, 20133 min read

Key points

  • Europe's main drugs regulator has found no new safety issues linked to Roche medicines after an investigation into the Swiss drugmaker, which was rapped last year for lax drug-safety reporting.
  • The investigation included 19 centrally approved drugs, several of which were for cancer.
  • The EMA initially put the potential number of unreported adverse events at 80,000, but this figure has since been revised down to around 23,000, a Roche spokesman said.
  • In the event, the EMA said its thorough review of drugs made by Roche had not identified any important new safety concerns.

Europe's main drugs regulator has found no new safety issues linked to Roche medicines after an investigation into the Swiss drugmaker, which was rapped last year for lax drug-safety reporting.

The European Medicines Agency (EMA) launched a probe into Roche in June 2012 after a routine inspection found it had failed to properly assess tens of thousands of cases of possible adverse drug reactions.

The investigation included 19 centrally approved drugs, several of which were for cancer. Roche is the world's largest maker of cancer medicines, as well as producing drugs for viral infections and inflammatory diseases.

Drugmakers are required to evaluate problems reported by doctors and patients after taking their drugs, and then pass on any serious cases to regulators. The Roche inspection found many of these reports had not been properly assessed by the company.

The EMA initially put the potential number of unreported adverse events at 80,000, but this figure has since been revised down to around 23,000, a Roche spokesman said.

The large number of unreported cases led to concerns that there might be unforeseen safety issues with some of Roche's medicines, which include widely used brands, such as Avastin and Herceptin, in cancer, and the influenza pill Tamiflu.

In the event, the EMA said its thorough review of drugs made by Roche had not identified any important new safety concerns.

"The balance of benefits and risks of these medicines has not been affected and there is no new advice regarding their use. Patients should continue to take these medicines as previously advised," the agency said in a statement.

Roche, however, could still face legal infringement procedures by the European authorities for failing to comply with so-called "pharmacovigilance" obligations.

The Basel-based drugmaker said it welcomed the conclusion of the EMA review, adding that it had put in place corrective actions concerning the collection, processing, evaluation and reporting of adverse event data.

The unusually wide-ranging investigation into Roche's medicines was triggered by a routine check of a Roche facility in Britain, which found it had not properly evaluated thousands of reports linked to a company-sponsored patient support program dating back to 1997.

These cases included a significant number of deaths, which may or may not have been linked to the medicines.

Adverse drug reporting is designed to catch potential problems with medicines by setting a requirement for notification when a patient dies or suffers a medical setback - even if this may be due to their underlying disease.

The EMA - the equivalent of the U.S. Food and Drug Administration (FDA) - routinely carries out pharmacovigilance inspections to make sure drug companies are reporting incidents properly.

###

By Ben Hirschler

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.